Literature DB >> 1561402

Undifferentiated spondyloarthropathies.

H Zeidler1, W Mau, M A Khan.   

Abstract

The term undifferentiated spondyloarthropathy (uSpA) refers to patients with clinical and roentgenographic features suggestive of spondyloarthropathies but not fulfilling the diagnostic or classification criteria for any of the currently established disease categories. The frequency and clinical spectrum of uSpA have been ignored in previous epidemiologic and clinical studies. A generally accepted nosologic concept and definition of uSpA may be needed to overcome this issue. So far the recently developed ESSG criteria have the broadest basis of consent, at least for several European centers. With the use of the ESSG classification criteria the real prevalence may be better defined in the future and the early classification of such patients in clinical practice should be advanced. Nevertheless, the diagnosis of uSpA is only a working label with the implicit demand to solve the clinical conundra by follow-up or even better by identifying the causative or triggering infectious agents.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1561402

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  20 in total

1.  Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up.

Authors:  E Kruithof; F Van den Bosch; D Baeten; A Herssens; F De Keyser; H Mielants; E M Veys
Journal:  Ann Rheum Dis       Date:  2002-03       Impact factor: 19.103

Review 2.  Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor alpha.

Authors:  F Van den Bosch; D Baeten; E Kruithof; F De Keyser; H Mielants; E M Veys
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

Review 3.  Ankylosing spondylitis: introductory comments on its diagnosis and treatment.

Authors:  M A Khan
Journal:  Ann Rheum Dis       Date:  2002-12       Impact factor: 19.103

4.  Clinically silent inflammatory gut lesions in undifferentiated spondyloarthropathies.

Authors:  L Altomonte; A Zoli; A Veneziani; L Mirone; G Santacesaria; C Chiarelli; F Federico; G Massi; M Magaro
Journal:  Clin Rheumatol       Date:  1994-12       Impact factor: 2.980

5.  The LMP2 polymorphism is associated with susceptibility to acute anterior uveitis in HLA-B27 positive juvenile and adult Mexican subjects with ankylosing spondylitis.

Authors:  W P Maksymowych; G S Jhangri; C Gorodezky; M Luong; C Wong; R Burgos-Vargas; M Morenot; J Sanchez-Corona; C Ramos-Remus; A S Russell
Journal:  Ann Rheum Dis       Date:  1997-08       Impact factor: 19.103

6.  Assessment of efficacy of pamidronate in undifferentiated spondyloarthropathy (uSpA): a placebo control trial in a tertiary level center.

Authors:  Rathindra Nath Sarkar; Sibaji Phaujdar; Dibyendu De; Kuntal Bhattacharyya
Journal:  Rheumatol Int       Date:  2011-12-27       Impact factor: 2.631

Review 7.  When is arthritis reactive?

Authors:  S S Hamdulay; S J Glynne; A Keat
Journal:  Postgrad Med J       Date:  2006-07       Impact factor: 2.401

8.  Commented glossary for rheumatic spinal diseases.

Authors:  J Braun; J Sieper
Journal:  Ann Rheum Dis       Date:  1996-01       Impact factor: 19.103

9.  Study of bone mineral density in patients with ankylosing spondylitis.

Authors:  Hatinder Jeet Singh; Kaur Nimarpreet; Sibadatta Das; Ashok Kumar; Shesh Prakash
Journal:  J Clin Diagn Res       Date:  2013-12-15

10.  Chlamydiae as etiologic agents in chronic undifferentiated spondylarthritis.

Authors:  John D Carter; Hervé C Gérard; Luis R Espinoza; Louis R Ricca; Joanne Valeriano; Jessica Snelgrove; Cynthia Oszust; Frank B Vasey; Alan P Hudson
Journal:  Arthritis Rheum       Date:  2009-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.